AzTrials
AzTrials

Kidney Disease, ChronicReDeDiaNCT07718568

Impact of Reducing the Dialysate Flow Rate in Chronic Hemodialysis on Dialysis Quality and Environmental Impact on Water Consumption

A study testing Dialysate flow at 400mL/min and Dialysate flow at 500mL/min in people with Kidney Disease, Chronic, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

In France, 60,000 patients are receiving renal replacement therapy via dialysis in 2022, 90% of whom are on hemodialysis. This technique is based on the principle of exchange across a membrane between the patient's blood and the dialysate. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Kidney Disease, Chronic
What is being tested?
Dialysate flow at 400mL/min and Dialysate flow at 500mL/min
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
1 siteFrance
Study dates
Jan 2027to Oct 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age > 18 years
  • No decompensated psychiatric disorder, acute or decompensated somatic condition
  • Patients on hemodialysis for more than 3 months
  • Dialysis schedule: 3 times per week for 4 hours each session
  • Stable vascular access (arteriovenous fistula or tunneled central catheter)
  • Blood flow > 300 mL/min
  • Anuric (urine output < 500 mL/24 h)
  • Dialysis method: hemodialysis or hemodiafiltration

Who cannot join

  • Age < 18 years
  • Patient on dialysis for < 3 months
  • Unstable vascular access
  • Blood flow rate < 300 mL/min
  • Urine output > 500 mL/day
  • Dialysis technique: hemofiltration
Show all 9Show fewer
  • Severe intercurrent condition (somatic or psychiatric)
  • Pregnant or breastfeeding patients.
  • Patients who are legally incapacitated, under guardianship, or under conservatorship

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site
  • Assistance Publique - Hôpitaux de Marseille

    Marseille

    Romain Vial, Dr, 04913883569 ext. +33, romain.vial@ap-hm.fr

Other trials in France

About this study

Official title: Non-inferiority Study on the Efficacy of Hemodialysis With Dialysate Flow Rates of 400 mL/Min Versus 500 mL/Min in a Population of Patients Undergoing Chronic Hemodialysis. Impact of Reducing the Dialysate Flow Rate in Chronic Hemodialysis on Dialysis Quality and Environmental Impact on Water Consumption

In France, 60,000 patients are receiving renal replacement therapy via dialysis in 2022, 90% of whom are on hemodialysis. This technique is based on the principle of exchange across a membrane between the patient's blood and the dialysate. The goal is to purify the patient's blood as effectively as possible by removing all solutes that have accumulated due to kidney failure. The dialysate is produced from municipal water, which is treated through several processes (reverse osmosis, filtration) to produce ultrapure water. Water consumption at the La Conception Hospital center in Marseille, which conducts 37,000 sessions per year (64 hemodialysis stations), is estimated at 120 m³ of water per day, which is discharged into the sewer system after use. In France, this would correspond to an estimated total consumption of nearly one million m³ of drinking water per year. In the context of climate change, which will lead to a reduction in water resources, it is important to rethink all aspects of water consumption. The investigator's reflection is part of a growing awareness of the environmental impact of dialysis within a working group of the Francophone Society of Nephrology, Dialysis, and Transplantation: "Green Dialysis." The quality of clearance depends on blood flow and dialysate flow rate (Qd). The Qd was set at 500 mL/min based on earlier studies that showed this flow rate corresponded to maximum clearance of urea and the main toxic solutes. These studies were conducted at a time when dialysis membranes were less efficient. Today, the investigators use membranes with higher exchange efficiency. Despite this, the investigators have not reevaluated the appropriateness of a Qd of 500 mL/min. The quality criterion in dialysis is a balanced urea Kt/V measurement >1.2 for a 4-hour session (target set at 1.4 with certain "single-pool" dialysis machine measurement techniques). At the ivnestigator's center, the average urea Kt/V is 1.55 in "single-pool" mode. Reducing the Qd could be done without risk to patients, even if it leads to a decrease in urea Kt/V. A Colombian study with 5 years of follow-up demonstrates patient safety with a Qd of 400 mL/min (vs. 500 mL/min), with no difference in mortality or dialysis efficacy. The study population was not representative of chronic dialysis patients; 10% regained renal function, and the final analysis included only 25 of the 71 patients enrolled.

Being tested
Dialysate flow at 400mL/min, Dialysate flow at 500mL/min
Keywords
Efficicency or Quality of Hemodialysis, Green Dialysis
Medical subject headings
Renal Insufficiency, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dialysate flow at 400mL/minOther

    Dialysate flow fixed at 400mL/min for one month.

  • Dialysate flow at 500mL/minOther

    Dialysate flow fixed at 500mL/min for one month.

Study groups in NCT07718568
Study groupRoleWhat they receive
Dialysate flow at 400mL/minExperimentalNot described
Receives: Other: Dialysate flow at 400mL/min
Dialysate flow at 500mL/minActive comparatorNot described
Receives: Other: Dialysate flow at 500mL/min

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mesure of Urea Kt/V

    Mesure of Urea clearance by two blood samples, after dialysis minus before dialyse (of urea blood sample), at Day 0 and Month 1

    Measured: Day 0, Month 1

Secondary outcomes (9)
  1. Mesure of Beta2-microglobulin clearance

    Mesure of Beta2-microglobulin clearance by two blood samples, after dialysis minus before dialyse (of urea blood sample), at Day 0 and Month 1

    Measured: Day 0, Month 1

  2. Potassium rate before dialysis

    Mesure of Potassium rate before dialysis (Blood sample), at Day 0 and Month 1

    Measured: Day 0, Month 1

  3. Phosphorus rate before dialysis

    Mesure of Phosphorus rate before dialysis (Blood sample), at Day 0 and Month 1

    Measured: Day 0, Month 1

  4. Bicarbonate rate before dialysis

    Mesure of bicarbonate rate before dialysis (Blood sample), at Day 0 and Month 1

    Measured: Day 0, Month 1

  5. Acid indol acetic dosage rate

    Blood sample before dialysis at Day 0 and Month 1

    Measured: Day 0, Month 1 - Only for patient in dialysis in Assistance Publique Hopitaux de Marseille

  6. Questionnaire The 5-level EQ-5D version (EQ-5D-5L)

    Questionnaries Quality of life EQ-5D-5L for patients, at Day 0 and Month 1. Scale ranging from 0 to 100, higher scores mean a better outcome.

    Measured: Day 0, Month 1

  7. Questionnaire The Kidney Disease Quality of Life 36-item short form survey (KDQoL)

    Questionnaries Quality of life for patients KDQoL, at Day 0 and Month 1. Scale ranging from 0 to 100, higher scores mean a better outcome.

    Measured: Day 0, Month 1

  8. Indoxyl sulfate dosing rate

    Blood sample before dialysis at Day 0 and Month 1

    Measured: Day 0, Month 1 - Only for patient in dialysis in Assistance Publique Hopitaux de Marseille

  9. Para cresyl sulfate dosage rate

    Blood sample before dialysis at Day 0 and Month 1

    Measured: Day 0, Month 1 - Only for patient in dialysis in Assistance Publique Hopitaux de Marseille

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2026
  2. Study startJan 2027 (estimated)
  3. Primary completionApr 2029 (estimated)
  4. Study completionOct 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07718568
Sponsor's protocol ID
RCAPHM25_0445
Other IDs
2025-A02924-45
Acronym
ReDeDia
Status last verified
Jul 2026
First submitted
7 Jul 2026
Last updated
22 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Dialysate flow at 400mL/min and Dialysate flow at 500mL/min in people with Kidney Disease, Chronic, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Romain Vial, Dr (0491383569 ext. + 33, Romain.vial@ap-hm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mesure of Urea Kt/V (time frame: Day 0, Month 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in